

Mrkt BUZZ Immunovia: New study and FDA choose not to appeal LDT ruling

Carlsquare Equity Research has published a comment on some recent news flow.

Read the full comment here.

About Carlsquare

Carlsquare is a global research firm and financial advisor, focusing on M&A, Equity
Research and Growth Equity. Carlsquare has 150 employees with deep sector knowledge in all 11
GICS sectors. The senior equity research team has extensive experience about the stock
environment and several business sectors. The team produces company research reports,
independent valuations and trading notes. The group have offices in Canada, Denmark, France,
Germany, Poland, Sweden, United Kingdom and United States. Read more

Contacts

MARKUS AUGUSTSSON

Head of Equity Research <u>markus.augustsson@carlsquare.com</u> +46 (0)76 235 03 20

NIKLAS ELMHAMMER

Senior Equity Analyst niklas.elmhammer@carlsquare.com +46 (0)70 898 39 59

Attachments

Mrkt BUZZ Immunovia: New study and FDA choose not to appeal LDT ruling